Principle of Assay
Human Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG ELISA Kit (A319525) is a 90 minute indirect Enzyme-Linked Immunosorbent Assay (iELISA) designed for the in vitro quantitative determination of human Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG in serum, plasma, tissue homogenates, and other biological fluids. A 96-well microtiter plate has been pre-coated with assay-specific antigen. Standards and samples are added to the wells, where Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG present in the samples binds to the immobilized antigen. Following incubation, unbound components are removed by washing and an HRP-conjugated detection antibody is added to the wells. This detection antibody binds the captured Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG to form an indirect immune complex. After further incubation and washing, TMB substrate solution is added to visualize the HRP enzymatic reaction. This produces a blue-coloured product that changes to yellow following addition of acidic stop solution. The intensity of the yellow colour is directly proportional to the amount of Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG captured in each well. The concentration of Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG is calculated by reading the absorbance at 450 nm and comparing the values with the standard curve.